- Home
- GNFT vs RIGL Comparison
GNFT vs RIGL Comparison
Compare GNFT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- RIGL
- Stock Information
- Founded
- GNFT 1999
- RIGL 1996
- Country
- GNFT France
- RIGL United States
- Employees
- GNFT N/A
- RIGL N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- RIGL Health Care
- Exchange
- GNFT Nasdaq
- RIGL Nasdaq
- Market Cap
- GNFT 202.6M
- RIGL 366.5M
- IPO Year
- GNFT 2019
- RIGL 2000
- Fundamental
- Price
- GNFT $3.63
- RIGL $19.53
- Analyst Decision
- GNFT Strong Buy
- RIGL Buy
- Analyst Count
- GNFT 1
- RIGL 5
- Target Price
- GNFT $13.00
- RIGL $36.80
- AVG Volume (30 Days)
- GNFT 9.4K
- RIGL 215.8K
- Earning Date
- GNFT 04-03-2025
- RIGL 03-04-2025
- Dividend Yield
- GNFT N/A
- RIGL N/A
- EPS Growth
- GNFT N/A
- RIGL N/A
- EPS
- GNFT 0.47
- RIGL 0.99
- Revenue
- GNFT $86,225,222.00
- RIGL $179,278,000.00
- Revenue This Year
- GNFT $145.20
- RIGL $14.19
- Revenue Next Year
- GNFT N/A
- RIGL $13.10
- P/E Ratio
- GNFT $7.81
- RIGL $19.73
- Revenue Growth
- GNFT 175.45
- RIGL 54.71
- 52 Week Low
- GNFT $3.11
- RIGL $7.48
- 52 Week High
- GNFT $6.42
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- GNFT 47.85
- RIGL 42.65
- Support Level
- GNFT $3.11
- RIGL $19.00
- Resistance Level
- GNFT $3.72
- RIGL $23.50
- Average True Range (ATR)
- GNFT 0.23
- RIGL 1.49
- MACD
- GNFT -0.02
- RIGL -0.28
- Stochastic Oscillator
- GNFT 56.85
- RIGL 21.54
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.